

Curetis AG

Corporate Fact Sheet



Company Overview

Curetis develops advanced molecular diagnostics for infectious diseases. Combining molecular biology and medtech experience, the company offers versatile solutions for the rapid and easy identification of pathogens and antibiotic resistances associated with severe bacterial infections. The company's Unyvero™ System enables hospitals and doctors to obtain results automatically within hours - current laboratory standards require several days of microbiology culture for the same task.

The company is being led by a team of managers with considerable experience in the molecular diagnostics and medtech industry (e.g. Agilent Technologies, Beckman Coulter, Epigenomics, Hewlett Packard, Philips Medical Systems) and has secured € 36.6 million in funding from leading European investors. Curetis and Sanofi Pasteur have signed a collaboration agreement regarding the potential use of the Unyvero™ Platform in a future global clinical trial.

The first product focuses on pneumonia diagnostics and is scheduled to enter clinical trials in due course. Market entry is expected for 2012.

Technology & Products

The company's Unyvero™ System is a versatile hardware platform for the detection of a broad panel of pathogens and antibiotic resistances from a single sample in one run. It processes disposable Unyvero™ Cartridges that come with all necessary reagents to complete the analysis from sample to result.

The Unyvero™ System enables nucleic acid-based testing of all clinically relevant sample types in a fully automated analysis process requiring only few, quick manual preparation steps. The analysis thus can be performed with minimal operator time and eliminates the need for skilled staff or special infrastructure.

Thereby, clinical information is available within a few hours and physicians treating patients with life-threatening conditions can make informed therapy decisions as early as possible.

The first Unyvero™ Cartridge, Unyvero™ P50, focuses on pathogen as well as antibiotic resistance testing for pneumonia. It simultaneously analyses 39 DNA targets. Cartridges for further applications, e.g. for surgical site infections, blood stream infections and tuberculosis, are in preparation.

Components of the Unyvero™ System

Lysator for the preparation of up to 4 patient samples in parallel (body fluids such as blood or urine as well as sputa, aspirates, bronchial lavages, etc.)

Analyzer for the processing of 2 cartridges in parallel (fully random access)

Cockpit for the control of up to 8 Analyzers

Cartridge for pathogen detection and characterization (for up to 100 analytes)

DNA- or RNA-based test results within a few hours by a fully automated, walk-

Quick Facts

Management Team

Oliver Schacht, PhD
Chief Executive Officer
Andreas Boos,
Chief Technology Officer
Johannes Bacher,
Chief Operating Officer
Dr. Gerd Luedke,
Director Bio-Assay
Development
Dr. Anne Thews,
Director Marketing &
Medical Affairs
Dr. Klaus Brinkmann,
Director Sales

Supervisory Board

Dr. Frank Mühlenbeck
(Chairman)
Hans-Günter Hohmann
Dr. Jörg Neermann
Dr. Holger Reithinger
Dr. Gerhard Ries
Detlef Sasse

Key Shareholders

aeris CAPITAL
LSP Life Sciences Partners
BioMedPartners
CD-Venture
Forbion Capital Partners
Roche Venture Fund
ERP-Startfonds of KfW
Bankengruppe


Founded: 2007

No. of Employees: 30

Funding: €36.6 million

Caution - Investigational device, limited by federal (or United States) law to investigational use. Products and documentation are not available to customers within the United States

away, easy to use platform.



Strategy and Market

Infections are the third most frequent cause of death in the developed world and the number one cause of death in emerging and resource-poor countries. The associated economic burden in industrialized countries is estimated to exceed € 30 billion each year. In the western world alone, over 25 million people are diagnosed each year with bacterial infections, posing a major burden for healthcare systems worldwide. Moreover, antibiotic-resistant pathogens in healthcare settings are a growing threat. Rapid detection is a very important part of containing this problem. However, there is still a huge unmet need for technologies to deliver accurate and comprehensive diagnostic information so that timely and sound antibiotic therapy decisions can be made.

Curetis is well prepared to target the global IVD market. The team's expertise covers the entire cycle from the identification of clinically relevant applications through product specification, development and design to manufacturing, marketing and commercialization. The cross-functional team works closely with Curetis' commercial, clinical and academic partners to best fulfill its customers' needs.

Upcoming Milestones in 2012 / 2013

- Start of pivotal clinical trial in Europe
- Start of clinical trial in the U.S. towards FDA submission
- Expected launch in Europe
- Completion of prospective clinical trial in EU and U.S.
- Expected FDA filing in the U.S.
- European sales & marketing organization
- Initiate R&D for new cartridges

Clinical Network

Prof. Dr. Ingo Autenrieth
Prof. Dr. Antoni Torres
Prof. Dr. Cornelius Knabbe
Prof. Dr. Olivier Denis
Prof. Dr. Jean-Louis Vincent
Prof. Dr. Christine Ginocchio
Prof. Dr. Marin Kollef
Prof. Dr. Carey-Ann Burnham

Contact

Curetis AG
Max-Eyth-Str. 42
71088 Holzgerlingen
Germany
Tel. +49 (7031) 49195-10
Fax +49 (7031) 49195-19
pr@curetis.com
www.curetis.com